News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Penn Medicine and CHOP Faculty Make the TIME100 Health List for CRISPR Gene Therapy Breakthrough
Two doctors were recognized by TIME as pioneers in healthcare for successfully treating KJ Muldoon.
Penn Received $7.8 Million from ARPA-H to Advance Lymphatic Imaging and AI-Driven Disease Detection
The project is led by Maxim Itkin, MD, Professor of Radiology at Penn Medicine and the director of Penn’s Center for Lymphatic Disorders.
T Cells Targeting Misformed Proteins to Treat Neurodegenerative and Muscular Diseases
By targeting disease-specific proteins, this antigen-specific immunotherapy aims to selectively eliminate damaged cells, potentially offering a more precise and effective treatment approach.
Multiple Penn Affiliated Startups are Finalists for Awards at Life Science PA’s Annual Awards Dinner and Showcase
Each year, Life Sciences PA hosts a celebration to honor the innovation and commitment members have made to the life sciences industry.
REGENXBIO Announces Positive Long-Term Data for Gene Therapy RGX-202 for Duchenne Muscular Dystrophy
REGENXBIO was co-founded by James Wilson, MD, PhD, Emeritus Professor of Medicine at Penn Medicine.
European Commission Expands Approval of Sobi’s Aspaveli® for Rare Kidney Diseases
Aspaveli ® is also approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) in the United States, European Union, and other countries globally.
GEMMA Biotherapeutic Announces Clinical Trial Authorization for New Gene Therapy Treatment
GEMMA announced that its novel gene therapy for spinal muscular atrophy type 1 (SMA1) has been cleared for clinical trial in Brazil.
Solid Biosciences Doses First Participant in First-in-Class Clinical Trial Evaluating Gene Therapy for the Treatment of Friedreich’s Ataxia
Initial trial data is expected in the second half of 2026.
Osetomics Appoints Global Medical Device Leader as CEO
The company is currently raising $8.5 million to support further development of its diagnostic and prognostic tools.
Vasowatch Receives $150K from Ben Franklin University Partners
Vasowatch received $150K from Ben Franklin Technology Partners.